Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study

Divya A. Parikh, Ali Raza Khaki, Stephen B. Williams

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)429-430
Number of pages2
JournalEuropean Urology
Issue number4
StatePublished - Apr 2022
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Cite this